NICE (UK) positive for Kimmtrak (tebentafusp) for treating advanced uveal melanoma – Immunocore Ltd

NICE (UK): 1.1 Tebentafusp is recommended, within its marketing authorisation, for treating HLA‑A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company provides it according to the commercial arrangement.

Why the committee made this recommendation: There is no standard treatment specifically for HLA‑A*02:01-positive unresectable or metastatic (advanced) uveal melanoma. Usually people are offered immunotherapies normally used for treating cutaneous melanoma, such as pembrolizumab, or chemotherapy. Tebentafusp aims to treat the specific features of HLA‑A*02:01-positive uveal melanoma. Clinical trial evidence suggests that tebentafusp could increase how long people live and how long they have before their cancer gets worse compared with usual treatment. Tebentafusp meets the criteria for a life-extending treatment at the end of life and is likely to increase how long people live. Accounting for uncertainty, the cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources. So, tebentafusp is recommended.